A lifestyle intervention program for the prevention of type 2 diabetes mellitus among South Asian women with gestational diabetes mellitus

Conditions

Gestational Diabetes

Gupta Y, Kapoor D, Lakshmi JK, Praveen D, Santos JA, Billot L, Naheed A, de Silva HA, Gupta I, Farzana N, John R, Ajanthan S, Bhatla N, Desai A, Pathmeswaran A, Prabhakaran D, Teede H, Zoungas S, Patel A, Tandon N, LIVING Collaborative Group.

2023-08-316 citations

10.1016/j.diabres.2023.110893

Effects of a Lifestyle Intervention to Prevent Deterioration in Glycemic Status Among South Asian Women With Recent Gestational Diabetes

Nikhil Tandon, Yashdeep Gupta, Deksha Kapoor, Josyula K. Lakshmi, Devarsetty Praveen et al. (100 authors)

JAMA Network Open2022-03-0258 citations

10.1001/jamanetworkopen.2022.0773

Lifestyle InterVention IN Gestational diabetes (LIVING) in India, Bangladesh and Sri Lanka: protocol for process evaluation of a randomised controlled trial

Janani Shanthosh, Deksha Kapoor, Josyula K. Lakshmi, Anushka Patel, Yashdeep Gupta et al. (11 authors)

BMJ Open2020-12-012 citations

10.1136/bmjopen-2020-037774

A lifestyle intervention programme for the prevention of Type 2 diabetes mellitus among South Asian women with gestational diabetes mellitus [LIVING study]: protocol for a randomized trial.

Gupta Y, Kapoor D, Josyula LK, Praveen D, Naheed A, Desai AK, Pathmeswaran A, de Silva HA, Lombard CB, Shamsul Alam D, Prabhakaran D, Teede HJ, Billot L, Bhatla N, Joshi R, Zoungas S, Jan S, Patel A, Tandon N.

2018-11-2914 citations

10.1111/dme.13850

Interventions

The study will be conducted in 4 hospital sites • Colombo North Teaching Hospital, Ragama • Colombo South Teaching Hospital, Kalubowila • Negombo District General Hospital • De Soysa Hospital for

Eligibility

Inclusion criteria

Inclusion criteria: Absence of type 2 diabetes mellitus (T2DM) as confirmed by findings of Impaired Glucose Tolerance, Impaired Fasting Glucose, Normal Glucose Tolerance at the at 6±3 months post-partum OGTT (Oral Glucose Tolerance Test)

Exclusion criteria

Exclusion criteria: 1. Place of residence outside the catchment of the treating hospital 2. Lack of access to a mobile telephone

Design outcomes

Primary

Measure	Time frame
Proportion of women with a change of glycaemic category, at or prior to final visit: • Normal glucose tolerance to impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) or T2DM • IFG or IGT to T2DM [At baseline and at the final visit. (The median follow up period of the study is 24 months and minimum follow up is 12 months.The end of study visit would be different for each participant depending on when they are randomized) ]	—

Measure

Time frame

Proportion of women with a change of glycaemic category, at or prior to final visit: • Normal glucose tolerance to impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) or T2DM • IFG or IGT to T2DM [At baseline and at the final visit. (The median follow up period of the study is 24 months and minimum follow up is 12 months.The end of study visit would be different for each participant depending on when they are randomized) ]

—

Secondary

Measure	Time frame
Percentage reduction in Fasting plasma glucose [At baseline and then 6 monthly until the end of the follow-up period.] Percentage reduction in : Area under the curve of OGTT [At baseline and then 6 monthly until the end of the follow-up period.] Percentage reduction in Body weight [At baseline and then 6 monthly until the end of the follow-up period. ] Percentage reduction in Waist circumference [At baseline and then 6 monthly until the end of the follow-up period. ] Percentage reduction in Systolic blood pressure [At baseline and then 6 monthly until the end of the follow-up period. ] Improvement of Physical activity level using the GPAQ (global physical activity questionnaire [At baseline and then 6 monthly until the end of the follow-up period. ] Improvement of Diet using 24 hour diet recall [At baseline and then 6 monthly until the end of the follow-up period. ] Improvement of Quality of life using the EQ5D questionnaire [At baseline and then 6 monthly until the end of the follow-up period. ] Affordability: will be measured using a specific health economic model using health care costs and outcomes both within trial and on long term basis. [At baseline and then 6 monthly until the end of the follow-up period. ]	—

Measure

Time frame

Percentage reduction in Fasting plasma glucose [At baseline and then 6 monthly until the end of the follow-up period.] Percentage reduction in : Area under the curve of OGTT [At baseline and then 6 monthly until the end of the follow-up period.] Percentage reduction in Body weight [At baseline and then 6 monthly until the end of the follow-up period. ] Percentage reduction in Waist circumference [At baseline and then 6 monthly until the end of the follow-up period. ] Percentage reduction in Systolic blood pressure [At baseline and then 6 monthly until the end of the follow-up period. ] Improvement of Physical activity level using the GPAQ (global physical activity questionnaire [At baseline and then 6 monthly until the end of the follow-up period. ] Improvement of Diet using 24 hour diet recall [At baseline and then 6 monthly until the end of the follow-up period. ] Improvement of Quality of life using the EQ5D questionnaire [At baseline and then 6 monthly until the end of the follow-up period. ] Affordability: will be measured using a specific health economic model using health care costs and outcomes both within trial and on long term basis. [At baseline and then 6 monthly until the end of the follow-up period. ]

—

Countries

Bangladesh,India,Sri Lanka

Contacts

Public ContactProf Asita de Silva

Director

asitades@gmail.comTel: +94 112665266

Outcome results

None listed